BACKGROUND: India is the diabetes capital with home to 69.1 million people with DM, the second highest number of cases after China.

This global burden of diabetes, brings with it the potential for a catastrophic increase in the prevalence of kidney and cardiovascular disease. Although the increased mortality in patients with diabetes traditionally has been attributed to coronary artery disease, more recent studies have emphasized the importance of chronic heart failure (HF) as a common and deadly comorbidity, to which the patient with nephropathy, even in its earliest stages, is especially prone. Diabetes mellitus may be one factor that specifically influences cardiac diastolic function, because  diabetes and impaired glucose tolerance selectively accelerate the deterioration of LV diastolic function.

METHODOLOGY: : A cross sectional study was conducted in GSL GENERAL HOSPITAL, Rajahmundry over a period of 18 months from Nov 2016 to April 2018 in  type 2 diabetes mellitus patients  department of general medicine. A total of 150 subjects were observed in this study. This study was done with a view to determine whether there is any association between diastolic dysfunction in type 2DM and Diabetic nephropathy.

RESULTS: Overall Mean age of study participants was 56.98 + 10.27 years with a range from 30 to 88 years. In the present study there was significant correlation between age, duration of Type 2 Diabetes, PPBS, HbA1c, UACR, serum creatinine, eGFR, Hb, USG showing renal parenchymal changes, ECG showing LVH, and Diabetic nephropathy with diastolic dysfunction.

CONCLUSION: Results of the present study reveals that there is significant evidence to support the conclusion that microalbuminuria or proteinuria in patients with diabetes is a potential risk factor not only for kidney function impairment but also a marker for high risk of cardiovascular complications.Type 2 DM subjects with and without nephropathy should be screened for sub clinical diastolic dysfunction by echocardiography.These patients should receive a multifactorial treatment and should be monitored carefully to prevent or slow down the progression of both kidney and cardiovascular complications